Tasso and Arup Laboratories have formed a collaboration for developing and ‘operationalising’ at-home, blood testing services, offering support to clinical research.
By combining Tasso’s clinical-grade blood collection technology with Arup’s testing services, which include more than 3,000 laboratory tests and test combinations, the partnership aims to expedite decentralised clinical research.
Go deeper with GlobalData
Arup performed validation for several assays, including for rheumatoid factor, high-sensitivity C-reactive protein, high-sensitivity DNA, and creatinine, for launching the collaboration.
These tests utilise capillary blood microsamples collected by Tasso’s devices.
The partnership plans to expand its offerings with additional applications, as well as assays, throughout the year and beyond, following the completion of validation protocols.
Tasso’s role in the partnership is pivotal, providing an end-to-end services platform that encompasses shipping and digital patient-facing solutions designed to ensure blood collection and logistics.
Arup innovation president Tracy George said: “By developing testing that is compatible with Tasso’s game-changing remote blood collection solutions, we will further increase participant access to clinical research.”
The medical directors at Arup, who are also faculty members at the University of Utah’s Spencer Fox Eccles School of Medicine Department of Pathology, bring their expertise to the test development and validation process.
Tasso co-founder and chief technology officer Erwin Berthier said: “Patient-centric testing solutions are needed to provide better access to clinical research and enable the development of personalised or predictive blood testing solutions.
“Tasso combining forces with Arup Laboratories, a trusted industry leader, enables us to provide gold standard remote testing solutions that remove barriers to adoption of decentralised testing.”
In June 2023, Arup Laboratories received the US Food and Drug Administration (FDA) approval for the AAV5 DetectCDx.
This companion diagnostic tool is crucial for identifying adult subjects eligible for treatment with Roctavian, a BioMarin Pharmaceutical-developed gene therapy.
